Evercore ISI upgraded Editas Medicine (EDIT) to Outperform from In Line with a $7 price target
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EDIT:
- Editas Medicine price target lowered to $11 from $17 at Stifel
- Editas Medicine price target lowered to $8 from $12 at Truist
- Editas Medicine price target lowered to $7 from $9 at Wells Fargo
- Editas Medicine price target lowered to $5 from $7 at Barclays
- Editas Medicine Reports Q3 2024 Results and Developments